72016-68-3

Basic information

• Product Name: ETHYL 2-(5-BROMO-2-METHYL-1H-INDOL-3-YL)ACETATE
• Synonyms: ETHYL (5-BROMO-2-METHYL-1H-INDOL-3-YL)ACETATE;ETHYL 2-(5-BROMO-2-METHYL-1H-INDOL-3-YL)ACETATE
• CAS NO: 72016-68-3
• Molecular Formula: C₁₃H₁₄BrNO₂
• Molecular Weight: 296.16
• Mol File: 72016-68-3.mol
• Article Data: 11

Chemical Properties

• Melting Point: 96-98 °C
• Boiling Point: 414.6±40.0 °C(Predicted)
• Appearance: /
• Density: 1.454±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 16.31±0.30(Predicted)
• CAS DataBase Reference: ETHYL 2-(5-BROMO-2-METHYL-1H-INDOL-3-YL)ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-(5-BROMO-2-METHYL-1H-INDOL-3-YL)ACETATE(72016-68-3)
• EPA Substance Registry System: ETHYL 2-(5-BROMO-2-METHYL-1H-INDOL-3-YL)ACETATE(72016-68-3)

Safety Data

• Hazardous Substances Data: 72016-68-3(Hazardous Substances Data)

Upstream product

• 64-17-5 ethanol 
• 71987-66-1 2-(5-bromo-2-methyl-1H-indol-3-yl)acetic acid 
• 100613-91-0 4-(4-bromo-phenylhydrazono)-valeric acid ethyl ester 
• 622-88-8 4-bromophenylhydrazine hydrochloride 
• 123-76-2 levulinic acid 
• 539-88-8 4-oxopentanoic acid ethyl ester 
• 589-21-9 (4-bromophenyl)hydrazine 
• 100613-91-0 4-[(4-bromo-phenyl)-hydrazono]-pentanoic acid ethyl ester 
• 1075-34-9 5-bromo-2-methyl-1H-indole 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 185063-91-6 5-bromo-2-methyl-1-(phenylmethyl)-1H-indole-3-acetic acid ethyl ester 
• 178383-49-8 [5-bromo-1-(4-bromo-benzyl)-2-methyl-1H-indol-3-yl]-acetic acid ethyl ester 
• 479422-11-2 ethyl [5-bromo-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]acetate 
• 479422-12-3 2-[5-bromo-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]ethanol 
• 479422-13-4 methyl 4-[2-[5-bromo-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]ethoxy]benzoate 
• 872675-07-5 methyl 4-[2-[1-(diphenylmethyl)-2-methyl-5-phenyl-1H-indol-3-yl]ethoxy]benzoate 
• 872675-09-7 methyl 4-[2-[1-(diphenylmethyl)-2-methyl-5-(morpholin-4-yl)-1H-indol-3-yl]ethoxy]benzoate 
• 178383-51-2 [5-bromo-1-(4-bromo-benzyl)-2-methyl-1H-indol-3-yl]-acetic acid 
• 163735-00-0 2-methyl-5-phenyl-1-(phenylmethyl)-1H-indole-3-acetic acid ethyl ester 
• 102173-18-2 (5-bromo-2-methyl-indol-3-yl)-acetic acid-(1-phenyl-ethylLiDenehydrazide) 
• 102159-67-1 (5-bromo-2-methyl-indol-3-yl)-acetic acid-(4-dimethylamino-benzylidenehydrazide) 

Relevant articles and documents

Indole compounds with: N-ethyl morpholine moieties as CB2 receptor agonists for anti-inflammatory management of pain: Synthesis and biological evaluation

The CB2 receptor plays a crucial role in analgesia and anti-inflammation. To develop novel CB2 agonists with high efficacy and selectivity, a series of indole derivatives with N-ethyl morpholine moieties (compounds 1-56) were designed, synthesized and biologically evaluated. Compounds 1, 2, 3, 46 and 53 exhibited high CB2 receptor affinity at low nanomolar concentrations and good receptor selectivity (EC50(CB1)/EC50(CB2) greater than 1000). The most active compound, compound 2, was more potent than the standard drug GW405833 for in vitro agonistic action on the CB2 receptor. More importantly, in a rat model for CFA-induced inflammatory hyperalgesia, compound 2 had a potent anti-inflammatory pain effect within 12 hours after administration. At the 1 h time point, compound 2 had a dose-dependent reversal for hyperalgesia with an estimated ED50 value of 1.097 mg kg-1. Moreover, compound 2 significantly suppressed the pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) in CFA-induced lesions. These protective effects of compound 2 on inflammatory pain were superior to those of GW405833, suggesting that compound 2 may be a promising therapeutic drug that needs further validation.

Discovery and refinement of a new structural class of potent peptide deformylase inhibitors

New classes of antibiotics are urgently needed to counter increasing levels of pathogen resistance. Peptide deformylase (PDF) was originally selected as a specific bacterial target, but a human homologue, the inhibition of which causes cell death, was rec

Hypoglycemic imidazoline compounds

This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.